Compare GSK plc (GSK) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares MSCI India ETF — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while iShares MSCI India ETF trades at $46.01 (market cap $5.73B). The key difference: GSK plc is far larger — about 16× iShares MSCI India ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares MSCI India ETF for 58 Days on average.
| GSK | INDA | |
|---|---|---|
Market Cap | $91.88B | $5.73B |
Volume | 7,730,529 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $55.29 |
52-Week Low | $43.24 | $45.42 |
Typical Hold Time | 93 Days | 58 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
INDA trades at $45.98, down 0.3% with bearish technical signals showing 19 sell indicators versus 5 buy signals. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and pharma sector export issues. Technical indicators show oversold conditions with RSI readings below 16, suggesting potential for near-term bounce despite the dominant bearish trend.
The outlook remains cautious as India's market composition with heavy banking sector exposure and external pressures from US tariff tensions create uncertainty. Key support at $45 provides critical technical level, while sector-specific challenges in technology and pharmaceuticals warrant careful monitoring of India's economic resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
